What is Bristol-Myers Squibb's camzyos — total revenues?

Bristol-Myers Squibb (BMY) reported camzyos — total revenues of $416M in Q2 2026.

How has Bristol-Myers Squibb's camzyos — total revenues changed year-over-year?

Bristol-Myers Squibb's camzyos — total revenues increased by 60.0% year-over-year, from $260M to $416M.

What does camzyos — total revenues mean?

This metric represents the total global net sales generated from the commercialization of Camzyos, a specialized therapeutic product. It reflects the market adoption, pricing power, and clinical demand for this specific treatment within the company's cardiovascular portfolio. As a key growth driver, this revenue stream is critical for assessing the company's success in launching and scaling high-value specialty medicines.

Bristol-Myers Squibb BMY Camzyos — Total Revenues

Other product segments

Eliquis

$4.48B+21.8%

Opdivo

$2.49B-2.9%

Orencia

$1.03B+7.4%

Yervoy

$769M+5.6%

Reblozyl

$735M+29.4%

Other Growth products

$653M+38.9%

Breyanzi

$484M+40.7%

Revlimid

$425M-49.3%

Opdualag

$349M+22.9%

Opdivo Qvantig

$261M+770%

Pomalyst/Imnovid

$204M-71.2%

Other Legacy products

$170M-23.8%

Zeposia

$169M+12.7%

Sprycel

$88M-26.7%

Sotyktu

$87M+24.3%

Cobenfy

$63M+80.0%

Abraxane

$55M-47.6%

Krazati

$55M+14.6%

Other revenue

-$9M—

Similar metrics at other companies

EXELCABOMETYX — Total revenues

$552.77M+8.2%

INCYPEMAZYRE — Total revenues

$23.42M+5.5%

OGNRosuzet — Revenue

$6M+50.0%

GILDYeztugo — Total revenues

$166M—

BMRNVOXZOGO — Total revenues

$219.88M+2.9%

PGENPapzimeos — Total revenues

$21.59M—

Other financials

Income statement

See full

Revenue$13.0B+5.7%

Gross profit$9.2B+3.9%

Net income$3.3B+153%

EPS (diluted)$1.62+153%

Balance sheet

See full

Cash & equivalents$8.7B-30.8%

Total debt$43.3B-12.3%

Total equity$22.3B+28.0%

Total assets$87.6B-7.4%

Cash flow

See full

Operating cash flow$3.4B-13.4%

CapEx$305.0M-15.5%

Free cash flow$3.1B-13.2%

Valuation

See full

Market cap$129.88B+36.2%

Enterprise value$164.48B+24.5%

P/E14×-5.2×

P/S2.6×+0.6×

Profitability

See full

Gross margin70.2%-0.1pp

Net margin18.9%+8.4pp

FCF margin23.3%-7.3pp

Returns & leverage

See full

Return on equity46.7%+17.8pp

Debt / equity1.9×-0.9×

Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's camzyos — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bristol-Myers Squibb's camzyos — total revenues?: Bristol-Myers Squibb (BMY) reported camzyos — total revenues of $416M in Q2 2026.
How has Bristol-Myers Squibb's camzyos — total revenues changed year-over-year?: Bristol-Myers Squibb's camzyos — total revenues increased by 60.0% year-over-year, from $260M to $416M.
What does camzyos — total revenues mean?: This metric represents the total global net sales generated from the commercialization of Camzyos, a specialized therapeutic product. It reflects the market adoption, pricing power, and clinical demand for this specific treatment within the company's cardiovascular portfolio. As a key growth driver, this revenue stream is critical for assessing the company's success in launching and scaling high-value specialty medicines.